Publications

PUBLICATIONS

Appraisal-specific

E Poku, J Rathbone, R Wong, E Everson-Hock, M Essat, A Pandor, A Wailoo. The safety of intravitreal bevacizumab monotherpay in adult ophthalmic conditions: systematic review. 2014 BMJ Open 4:e005244 doi:10.1136/bmjopen-2014-005244

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; Vol 47 (10): 1590

A Wailoo, N Bansback, J Chilcott. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance Rheumatology 2008; Vol 47 (2): 119-120

A Wailoo, A Sutton, A Morgan. The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009British Journal of Cancer Vol 100: 436-441

S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.

Methods development

M Hernández Alava, A Wailoo. ALDVMM: A command for fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. The Stata Journal 2015 In press. Available online.

B Pennington, S Davis. Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health 17(8):762-771 Dec 2014

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: a stated preference discrete choice experiment. Social Science & Medicine 2015; 124:48-56 (first published online November 2014)

M Hernández Alava, A Wailoo, F Wolfe, K Michaud. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Medical Decision Making 2014; 34:919-930 (first published online 2013 doi:10.1177/0272989X13500720)

O Ciani, S Davis, P Tappenden, R Garside, K Stein, A Cantrell, E D Saad, M Buse, R S Taylor Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers International Journal of Technology Assessment in Health Care 2014; 30 (3): 312-324

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: an empirical study of public preferences. European Journal of Health Economics 2014; 15 (4):389-399 (first published online May 2013; DOI 10.1007/s10198-013-0482-3)

B Kearns, R Ara, A Wailoo, A Manca, M Hernandez Alava, K Abrams, M Campbell. Good practice guidelines for the use of statistical regression models in economic evaluations. PharmacoEconomics (2013); 31 (8): 643-652

Thokala P, Duenas A The applicability of Multi Criteria Decision Analysis for Health Technology Assessment. Value in Health 2012; 15(8): 1172-1181

S Davis, A Wailoo. A review of the psychometric performance of the EQ-5D in people with urinary incontinence. Health and Quality of Life Outcomes 2013; 11 (20)

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: an exploratory preference elicitation study. HEDS Discussion Paper 11/17

J Morden, P Lambert, N Latimer, K Abrams, A Wailoo. Assessing methods for dealing with treatment switching in randomised clinical trials: A simulation study BMC Medical Research Methodology 2011; Vol 11:4

A Wailoo, A Tsuchiya, C McCabe. Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected. Pharmacoeconomics 2009; Vol 27 (12): 983-989

A Wailoo, A Sutton, N Cooper, D Turner, K Abrams, A Brennan, K Nicholson. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value in Health 2008; Vol 11 (2): 160-171.

Technical Support Documents

Evidence synthesis

S Dias, N Welton, A Sutton, A Ades. Evidence Synthesis for Decision Making 1: Introduction Med Decis Making July 2013 33: 597-606, doi:10.1177/0272989X13487604

S Dias, A Sutton, A Ades, N Welton. Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials Med Decis Making July 2013 33: 607-617, first published on October 26, 2012 doi:10.1177/0272989X12458724

S Dias, A Sutton, N Welton, A Ades. Evidence Synthesis for Decision Making 3: Heterogeneity-Subgroups, Meta-Regression, Bias, and Bias-Adjustment Med Decis Making July 2013 33: 618-640, doi:10.1177/0272989X13485157

S Dias, N Welton, A Sutton, D Caldwell, G Lu, A Ades Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials Med Decis MakingJuly 2013 33:641-656, doi:10.1177/0272989X12455847

S Dias, N Welton, A Sutton, A Ades. Evidence Synthesis for Decision Making 5: The Baseline Natural History Model Med Decis MakingJuly 2013 33:657-670, doi:10.1177/0272989X13485155

S Dias, A Sutton, N Welton, A Ades. Evidence Synthesis for Decision Making 6: Embedding Evidence Synthesis in Probabilistic Cost-effectiveness Analysis Med Decis MakingJuly 2013 33: 671-678, doi:10.1177/0272989X13487257

A Ades, D Caldwell, S Reken, N Welton, A Sutton, S Dias. Evidence Synthesis for Decision Making 7: A Reviewer’s Checklist Med Decis Making July 2013 33:679-691, doi:10.1177/0272989X13485156

Utilities

Papaioannou, J Brazier, S Paisley. Systematic searching and selection of health state utility values from the literature. Value in Health (2013); 16 (4): 686-695

L Longworth, D Rowen. Mapping to obtain EQ-5D utility values for use in NICE Health Technology Appraisals. Value in Health (2013); 16 (1): 202-210

R Ara, A Wailoo. Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies. Value in Health (2012) 15: 6.

Survival analysis

N. Latimer. Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Inconsistencies, limitations, and a practical guide. Medical Decision Making (2013) 33 (6): 743-754

A. Bagust, S. Beale. Survival analysis and extrapolation modeling of time-to-event clinical trail data for economic evaluation: an alternative approach. Medical Decision Making 2013; doi: 10.1177/0272989X13497998

N. Latimer. Response to “Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach” by Bagust and Beal. Medical Decision Making 2013; doi: 10.1177/0272989X13511302

Methods Guide update process 2008

Miners, A.(2008) Estimating ‘costs’ for cost-effectiveness analysis. Pharmacoeconomics Vol:26(9):745-751

Sutton, A.,Ades, AE.,Cooper, N.,Abrams, K.(2008) Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics Vol:26 (9): 753-767

Sculpher, M.(2008) Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics Vol: 26 (9): 799-806

McCabe,C.,Claxton,K.,Culyer, AJ.(2008) The NICE cost-effectiveness threshold. What it is and what that means. Pharmacoeconomics Vol: 26 (9): 733-744

Claxton, K.(2008) Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics Vol: 26: 781-798

Brazier, J.(2008) Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics Vol: 26 (9): 769-779